Cell Notes: From Readiness to Resilience: Building the CGT Workforce for an Adaptive Future

In her monthly column "Cell Notes," AABB's Christina Celluzzi, PhD, MS, CABP(H), shares insights, findings and commentary on emerging topics in biotherapies. This piece concludes a three-part “Cell Notes” series examining how regulatory flexibility is reshaping cell and gene therapy (CGT) development, delivery and the workforce that supports it. Subscribe to CellSource to receive "Cell Notes" and biotherapies updates from AABB directly in your inbox. 

In the first two parts of this series, I examined why regulatory flexibility is emerging and what operational readiness looks like in practice. For readers joining here, the central theme remains the same: cell and gene therapy (CGT) development is iterative, and regulatory models are evolving to support continuous learning. The question now becomes how to build a workforce capable of sustaining that model over time.

Regulatory flexibility assumes continued learning throughout development and into clinical use. Manufacturing processes evolve, analytical methods mature and new clinical insights reshape decision making. In this environment, workforce resilience becomes essential. Teams must be prepared not only to respond to change, but to anticipate it, manage it consistently and remain aligned across roles and functions.

This shift elevates expectations for training and professional development. Technical skills remain foundational, but they are no longer sufficient on their own. CGT professionals increasingly need to interpret data in context, document and justify change clearly, and communicate effectively across clinical, manufacturing, quality and regulatory disciplines. These capabilities help ensure that flexibility strengthens, rather than weakens, control.

Organizations that build resilient teams tend to invest in:

• Shared understanding, not just individual expertise: A common language around risk, quality and lifecycle thinking supports aligned decisions as programs evolve.

• Cross-functional exposure: Experience across disciplines strengthens judgment and supports consistency as therapies move toward broader clinical use.

• Preservation of institutional knowledge: Structured learning, mentorship and strong documentation help maintain continuity as teams grow or change.
  

Resilience is not about rigidity, but about the ability to adapt while maintaining control and alignment. A resilient workforce can evolve processes without losing sight of patient impact.

As CGT continues to advance, regulatory flexibility, operational readiness and workforce resilience increasingly shape an ecosystem where innovation can progress responsibly and sustainably.